Market Outpaces Growth of Overall World Pharmaceutical Sales
ARLINGTON, Va., May 31 /PRNewswire/ -- Friedman, Billings, Ramsey & Co.,
Inc., a subsidiary of Friedman, Billings, Ramsey Group, Inc. (NYSE: FBR),
today identified 12 mid- and small-capitalization companies that are expected
to benefit from trends that are driving an increase in the demand for central
nervous system drugs, including advances in biotechnology and health problems
faced by an aging population.
The 48-page report by Equity Analyst Jesse Schulman, Ph.D, identifies the
$48.4 billion market for pharmaceuticals that treat conditions that afflict
the central nervous system (CNS) including strokes, schizophrenia, multiple
sclerosis, and depression. Among the factors driving demand are the lack of
good treatments for many CNS disorders, such as Alzheimer's disease, which
leaves the market wide open for new and more effective drugs, and the aging
Baby Boom population who face increasing risk of age-related CNS disorders,
such as stroke.
"Central nervous system drug discovery and development is an attractive
field for investors," said Dr. Schulman. "The coming years are likely to
bring important new therapies into the marketplace from which far-sighted
investors can benefit," he said.
Mid- and small-capitalization companies have the most to gain from CNS
drug discovery and development. Although several major pharmaceutical
companies have extensive and successful franchises in CNS therapeutics, many
find their research establishment unable to create new drugs at the rate
needed to maintain acceptable growth. They are therefore forced to outsource
to small biotechnology companies.
The report is the first in a series of in-depth research reports from
FBR's expanding London office. The 12 companies covered in this report are H
Lundbeck A/S (LUN DC); Elan Corporation, Plc (NYSE: ELN) (ELA LN); Shire
Pharmaceuticals Group Plc (SHP LN); Vernalis Group Plc (VER LN)
(Nasdaq: VNGPF); Sanochemia Pharmazeutika AG (SAC NM); NeuroSearch A/S (NRSH
DC); CeNeS Pharmaceuticals Plc (CEN LN); ReNeuron Limited (REN LN); Genset SA
(GNST FP); deCODE genetics, Inc. (Nasdaq: DCGN); NicOx SA (NICO FP); and
Oxford BioMedica Plc (OXB LN).
Friedman, Billings, Ramsey Group, Inc. (NYSE: FBR), the parent company of
Friedman, Billings, Ramsey & Co., Inc., is a financial holding company for
investment banking, institutional brokerage, specialized asset management, and
banking products and services. FBR provides capital and financial expertise
throughout a company's lifecycle and affords investors access to a range of
proprietary financial products and services. Headquartered in the Washington
metropolitan area, FBR has offices in Arlington and Reston, Va., Bethesda,
Md., Boston, Charlotte, Chicago, Cleveland, Dallas, Irvine, Ca., New York
City, Portland, Seattle, London, and Vienna. Bank products and services are
offered by FBR National Bank & Trust, member FDIC and an Equal Housing Lender.
For more information, see http://www.fbr.com .
This report was prepared by Friedman Billings Ramsey & Co., Inc. (FBR &
Co) or one of its affiliates (collectively FBR) based on information available
to the public. This report does not represent an offer or a solicitation to
buy or sell any security or to pursue any trading strategy. The information
included herein is believed to be reliable, but FBR makes no representation as
to the accuracy or completeness of such information. The opinions expressed
herein are subject to change without notice.
Additional information concerning the securities mentioned in this report
is available upon request. FBR, and or its affiliates, or their respective
officers, directors, and employees (and their family members) may hold long or
short positions in the securities discussed herein. Securities discussed are
not FDIC insured, guaranteed by any bank, and may lose value. Because of
differing client objectives, this report should not be construed as advice
designed to meet the particular needs of any investor. Securities denominated
in foreign currency typically involve certain currency risks, which may affect
the value of the security and the income derived therefrom. In the U.S. this
report is approved and distributed by FBR & Co. In the United Kingdom this
report is approved and distributed by Friedman Billings Ramsey International
Limited (FBRIL), which is regulated by the Securities and Futures Authority
(SFA), and is not for distribution to private customers (as defined by the
SFA) and no financial instruments discussed herein will be made available to
such private customers. No part of this material may be copied or duplicated
in any form or by any means, or redistributed without the prior written
consent of FBR.
Friedman, Billings, Ramsey & Co., Inc. is a member of the National
Association of Securities Dealers, CRD number 25027.
MAKE YOUR OPINION COUNT - Click Here
SOURCE Friedman, Billings, Ramsey & Co., Inc.
/CONTACT: Michael W. Robinson of Friedman, Billings, Ramsey & Co., Inc.,
703-312-1830 or email@example.com/
/Web site: http://www.fbr.com/
(FBR ELN VNGPF DCGN)
CO: Friedman, Billings, Ramsey & Co., Inc.; Friedman, Billings, Ramsey Group,
Inc.; H Lundbeck A-S; Elan Corporation, Plc; Shire Pharmaceuticals Group
Plc; Vernalis Group Plc; Sanochemia Pharmazeutika AG; NeuroSearch A/S;
CeNeS Pharmaceuticals Plc; ReNeuron Limited; Genset SA; deCODE genetics,
Inc.; NicOx SA; Oxford BioMedica Plc
ST: Virginia, England
IN: HEA MTC
-0- May/31/2001 18:12 GMT
Press spacebar to pause and continue. Press esc to stop.